Severe, long-standing DME with cystoid changes, subretinal detachment, and high inflammatory cytokine burden tends to respond better to dual ANG2/VEGF-A inhibition than VEGF monotherapy. Faricimab ...

REGENXBIO Inc. (NASDAQ:RGNX) Q4 2025 Earnings Call Transcript March 5, 2026 REGENXBIO Inc. misses on earnings expectations. Reported EPS is $-1.3 EPS, expectations were $-1.01. Operator: Thank you for ...

Researchers use single-cell analysis to show how transplanted neural stem cells interact with the retina to preserve vision in retinitis pigmentosa.

Good morning, and welcome to Ocugen's Fourth Quarter and Full Year 2025 Financial Results and Business Update [Operator Instructions] I will now turn the call over to Tiffany Hamilton, Ocugen's Head ...

A look at the biologics, gene therapies, and vaccines most likely to reshape care —and manufacturing—in the year ahead.